Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
14 nov. 2024 16h30 HE
|
Traws Pharma, Inc.
COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
08 oct. 2024 07h30 HE
|
Traws Pharma, Inc.
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability...
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
30 sept. 2024 07h30 HE
|
Traws Pharma, Inc.
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study...
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
20 sept. 2024 07h30 HE
|
Traws Pharma, Inc.
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of...
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
17 sept. 2024 16h05 HE
|
Traws Pharma, Inc.
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
15 août 2024 07h00 HE
|
Traws Pharma, Inc.
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical...
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
14 août 2024 16h30 HE
|
Traws Pharma, Inc.
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral...
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
23 mai 2024 08h00 HE
|
Traws Pharma, Inc.
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
16 mai 2024 09h29 HE
|
Traws Pharma, Inc.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
07 mai 2024 08h00 HE
|
Traws Pharma, Inc.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy